These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 15504835

  • 1. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
    Herget T, Freitag M, Morbitzer M, Kupfer R, Stamminger T, Marschall M.
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
    [Abstract] [Full Text] [Related]

  • 2. The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors.
    Hutterer C, Hamilton S, Steingruber M, Zeitträger I, Bahsi H, Thuma N, Naing Z, Örfi Z, Örfi L, Socher E, Sticht H, Rawlinson W, Chou S, Haupt VJ, Marschall M.
    Antiviral Res; 2016 Oct; 134():130-143. PubMed ID: 27515131
    [Abstract] [Full Text] [Related]

  • 3. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy.
    Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T.
    J Gen Virol; 2002 May; 83(Pt 5):1013-1023. PubMed ID: 11961255
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97.
    Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T.
    J Gen Virol; 2001 Jun; 82(Pt 6):1439-1450. PubMed ID: 11369889
    [Abstract] [Full Text] [Related]

  • 5. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase.
    Zimmermann A, Wilts H, Lenhardt M, Hahn M, Mertens T.
    Antiviral Res; 2000 Oct; 48(1):49-60. PubMed ID: 11080540
    [Abstract] [Full Text] [Related]

  • 6. Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay.
    Mett H, Hölscher K, Degen H, Esdar C, De Neumann BF, Flicke B, Freudenreich T, Holzer G, Schinzel S, Stamminger T, Stein-Gerlach M, Marschall M, Herget T.
    J Biomol Screen; 2005 Feb; 10(1):36-45. PubMed ID: 15695342
    [Abstract] [Full Text] [Related]

  • 7. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
    Gilbert C, Boivin G.
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
    [Abstract] [Full Text] [Related]

  • 8. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
    Cihlar T, Fuller MD, Mulato AS, Cherrington JM.
    Virology; 1998 Sep 01; 248(2):382-93. PubMed ID: 9721246
    [Abstract] [Full Text] [Related]

  • 9. The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host.
    Michel D, Mertens T.
    Biochim Biophys Acta; 2004 Mar 11; 1697(1-2):169-80. PubMed ID: 15023359
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
    Neyts J, De Clercq E.
    Verh K Acad Geneeskd Belg; 1994 Mar 11; 56(6):561-92. PubMed ID: 7892749
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
    Drew WL, Miner RC, Marousek GI, Chou S.
    J Clin Virol; 2006 Oct 11; 37(2):124-7. PubMed ID: 16962820
    [Abstract] [Full Text] [Related]

  • 15. Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity.
    Wagner M, Michel D, Schaarschmidt P, Vaida B, Jonjic S, Messerle M, Mertens T, Koszinowski U.
    J Virol; 2000 Nov 11; 74(22):10729-36. PubMed ID: 11044117
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
    Webel R, Hakki M, Prichard MN, Rawlinson WD, Marschall M, Chou S.
    J Virol; 2014 May 11; 88(9):4776-85. PubMed ID: 24522923
    [Abstract] [Full Text] [Related]

  • 18. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo.
    Schleiss M, Eickhoff J, Auerochs S, Leis M, Abele S, Rechter S, Choi Y, Anderson J, Scott G, Rawlinson W, Michel D, Ensminger S, Klebl B, Stamminger T, Marschall M.
    Antiviral Res; 2008 Jul 11; 79(1):49-61. PubMed ID: 18329738
    [Abstract] [Full Text] [Related]

  • 19. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J, Boivin G.
    Antiviral Res; 2019 Mar 11; 163():91-105. PubMed ID: 30690043
    [Abstract] [Full Text] [Related]

  • 20. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
    Baldanti F, Lilleri D, Campanini G, Comolli G, Ridolfo AL, Rusconi S, Gerna G.
    J Antimicrob Chemother; 2004 Mar 11; 53(3):536-9. PubMed ID: 14739146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.